Effects of meta-chlorophenylpiperazine on cerebral blood flow in obsessive-compulsive disorder and controls

Biological Psychiatry

Volumn 44, Issue 5, 1998, Pages 367-370

  Ho Pian, Kamini L ^a   Westenberg, Herman G M ^a   Den Boer, Johan A ^a   De Bruin, Wieger I ^a   Van Rijk, Peter P ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cerebellum; Cerebral blood flow; Meta chlorophenylpiperazine; Obsessive compulsive disorder; Single photon emission computed tomography; Symptom provocation

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; PLACEBO; SEROTONIN AGONIST;

ADULT; ARTICLE; BRAIN BLOOD FLOW; BRAIN REGION; CEREBELLUM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; OBSESSION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTONINERGIC SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; CEREBROVASCULAR CIRCULATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; OBSESSIVE-COMPULSIVE DISORDER; PIPERAZINES; SEROTONIN AGONISTS;

EID: 0345267247     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(97)00458-7     Document Type: Article

References (30)

1. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. 1994;American Psychiatric Press, Washington, DC.
2. Barinaga M. The cerebellum Movement coordinator or much more? Science. 272:1996;482-483.
3. Baxter L.R., Phelps M.E., Mazziotta J.C., Guze B.H., Schwartz J.M., Selin C.E. Local cerebral glucose metabolic rates in obsessive-compulsive disorder. A comparison with rates in unipolar depression and in normal controls [published erratum appears in Arch Gen Psychiatry 1987;44:800]. Arch Gen Psychiatry. 44:1987;211-218.
4. Baxter L.R., Schwartz J.M., Mazziotta J.C., et al. Cerebral glucose metabolic rates in nondepressed patients with obsessive-compulsive disorder. Am J Psychiatry. 145:1988;1560-1563.
5. Baxter L.R., Schwartz J.M., Bergman K.S., et al. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatry. 49:1992;681-689.
6. Benkelfat C., Nordahl T.E., Semple W.E., King A.C., Murphy D.L., Cohen R.M. Local cerebral glucose metabolic rates in obsessive-compulsive disorder. Patients treated with clomipramine. Arch Gen Psychiatry. 47:1990;840-848.
7. Charney D.S., Goodman W.K., Price L.H., Woods S.W., Rasmussen S.A., Heninger G.R. Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Arch Gen Psychiatry. 45:1988;177-185.
8. Clomipramine in the treatment of patients with obsessive compulsive disorder. Arch Gen Psychiatry. 48:1991;730-738.
9. Gao J.H., Parsons L.M., Bower J.M., Xiong J., Li J., Fox P.T. Cerebellum implicated in sensory acquisition and discrimination rather than motor control. Science. 272:1996;545-547.
10. Goodman W.K., Price L.H., Rasmussen S.A., et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry. 46:1989;1006-1011.
11. Goodman W.K., McDougle C.J., Price L.H., et al. m-Chlorophenylpiperazine on patients with obsessive compulsive disorder Absence of symptom exacerbation . Biol Psychiatry. 38:1995;138-149.
12. Greist J.H., Jefferson J.W., Kobak K.A., Katzelnick D.J., Serlin R.C. Efficacy and tolerability of serotonin transport inhibitors in obsessive compulsive disorder, a meta-analysis. Arch Gen Psychiatry. 52:1995;53-60.
13. Hoehn Saric R., Pearlson G.D., Harris G.J., Machlin S.R., Camargo E.E. Effects of fluoxetine on regional cerebral blood flow in obsessive compulsive patients. Am J Psychiatry. 148:1991;1243-1245.
14. Hollander E., DeCaria C.M., Nitescu A., et al. Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry. 49:1992;21-28.
15. Hollander E., Prohovnik I., Stein D.J. Increased cerebral blood flow during m-CPP exacerbation of obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci. 7:1995;485-490.
16. Jenike M.A., Breiter H.C., Baer L., et al. Cerebral structural abnormalities in obsessive-compulsive disorder - A quantitative morphometric magnetic resonance imaging study. Arch Gen Psychiatry. 53:1996;625-632.
17. Leiner H.C., Leiner A.L., Dow R.S. Does the cerebellum contribute to mental skills? Behav Neurosci. 100:1986;443-454.
18. Leiner H.C., Leiner A.L., Dow R.S. Reappraising the cerebellum What does the hindbrain contribute to the forebrain? Behav Neurosci. 103:1989;998-1008.
19. Lucey J.V., Costa D.C., Blanes T., et al. Regional cerebral blood flow in obsessive-compulsive disordered patients at rest - Differential correlates with obsessive-compulsive and anxious-avoidant dimensions. Br J Psychiatry. 167:1995;629-634.
20. McGuire P.K., Bench C.J., Frith C.D., Marks I.M., Frackowiak R.S.J., Dolan R.J. Functional anatomy of obsessive-compulsive phenomena. Br J Psychiatry. 164:1994;459-468.
21. McNair D.M., Lorr M., Droppelman L.F. Manual for the Profile of Mood States. 1971;Educational and Industrial Testing Service, San Diego, CA.
22. Nordahl T.E., Benkelfat C., Semple W.E., Gross M., King A.C., Cohen R.M. Cerebral glucose metabolic rates in obsessive compulsive disorder. Neuropsychopharmacology. 2:1989;23-28.
23. Pigott T.A., Zohar J., Hill J.L., et al. Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder. Biol Psychiatry. 29:1991;418-426.
24. Pigott T.A., Hill J.L., Grady T.A., et al. A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to i.v. mCPP. Biol Psychiatry. 33:1993;3-14.
25. Rauch S.L., Jenike M.A., Alpert N.M., et al. Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography. Arch Gen Psychiatry. 51:1994;62-70.
26. Rubin R.T., Ananth J., Villanueva-Meyer J., Trajmar P.G., Mena I. Regional xenon-133 cerebral blood flow and cerebral Tc-99m-HMPAO uptake in patients with obsessive-compulsive disorder before and during treatment. Biol Psychiatry. 38:1995;429-437.
27. Schmahmann J.D. An emerging concept. The cerebellar contribution to higher function. Arch Neurol. 48:1991;1178-1187.
28. Swedo S.E., Schapiro M.B., Grady C.L., et al. Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Arch Gen Psychiatry. 46:1989;518-523.
29. Swedo S.E., Pietrini P., Leonard H.L., et al. Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Revisualization during pharmacotherapy. Arch Gen Psychiatry. 49:1992;690-694.
30. Zohar J., Mueller E.A., Insel T.R., Zohar Kadouch R.C., Murphy D.L. Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls. Arch Gen Psychiatry. 44:1987;946-951.